Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
IPO Year: 2015
Exchange: NASDAQ
Website: zosanopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2022 | Buy → Neutral | BTIG |
FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success." Elaine M
FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad range of leadership roles across operations, strategic planning, manufacturing and supply chain management, quality and regulatory affairs and new product development. "Kathy is an exceptional addition to the board, bringing deep experience across many functional areas, and we are thrilled to have her join our board," said Steven Lo, president and chief executive officer of Zosano. "As we work to
SC 13G - Zosano Pharma Corp (0001587221) (Subject)
FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 ("Chapter 11") of the United States Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a "debtor-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. Zosano
PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle Patch Emergex's COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex', or the ‘Company'), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation's (NASDAQ:ZSAN) proprietary microneedle patch system. Zosano's patch consists of
FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared with a net loss of $8.1 million, or $2.73 per share on a basic and diluted basis, for the same quarter in 2021. Research and development expenses for the first quar
FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its M207 New Drug Application. However, in order to preserve its capital and cash resources, Zosano has suspended its M207 program. Additionally, the company's remaining feasibility study with a pharmaceutical partner is expected to conclude this quarter. Zosano recently implemented an additional workforce reduction impacting approximately 40% of its remaining employees and suspended GMP manufacturi
FREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company's common stock. The reverse stock split will become effective today, April 11, 2022. The company's common stock is expected to begin trading on a split-adjusted basis when the markets open on April 12, 2022 under the existing trading symbol "ZSAN." The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP num
FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. "We are in discussions with the FDA to determine if there is a viable option to pursue approval of M207 using the currently available clinical data. In addition, we are actively evaluating financial and strategic alternatives in collaboration with external advisors, with a goal of maximizing value," said Steven Lo, president and chief executive officer of Zosano. "We believe our proprietary transdermal microneedle patch technology offer
FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years from the date of issuance. Zosano has granted the underwriter a 30-day option to purchase up to an additional 7,687,500 shares of common stock and/or additional warrants to purchase up to 7,687,500 s
FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Maxim Group LLC is acting as the sole book-running manager for the proposed offering. A registration statement relating to these securities has been filed with th
FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, "Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System" in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels that met EMEA's three guidelines for influenza vaccine efficacy and was generally well tolerated. "We are excited to report these results, which show that a lowe
FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success." Elaine M
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
3 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
25-NSE - Zosano Pharma Corp (0001587221) (Subject)
8-K - Zosano Pharma Corp (0001587221) (Filer)
8-K - Zosano Pharma Corp (0001587221) (Filer)
8-K - Zosano Pharma Corp (0001587221) (Filer)
10-Q - Zosano Pharma Corp (0001587221) (Filer)
8-K - Zosano Pharma Corp (0001587221) (Filer)
8-K - Zosano Pharma Corp (0001587221) (Filer)
10-K/A - Zosano Pharma Corp (0001587221) (Filer)
8-K - Zosano Pharma Corp (0001587221) (Filer)
S-8 - Zosano Pharma Corp (0001587221) (Filer)
BTIG downgraded Zosano Pharma from Buy to Neutral
Maxim Group reiterated coverage of Zosano Pharma with a rating of Buy and set a new price target of $2.50 from $1.50 previously